Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Nanosonics Limited ( (AU:NAN) ).
UBS Group AG and its related entities have notified Nanosonics Limited that they have ceased to be a substantial shareholder in the company as of 28 January 2026, reducing their holding below the substantial shareholding threshold under Australian corporate law. The change in UBS’s position may alter Nanosonics’ institutional shareholder base and could impact perceptions of market support and liquidity for the stock, although no change in the company’s operations or governance was indicated in the notice.
The most recent analyst rating on (AU:NAN) stock is a Hold with a A$4.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
More about Nanosonics Limited
Nanosonics Limited is a medical technology company specialising in infection prevention, best known for its automated high-level disinfection systems used primarily in healthcare settings. The company focuses on improving patient safety and clinical efficiency through innovative, automated decontamination solutions for medical instruments, with a strong presence in hospitals and clinics where infection control is a critical operational priority.
Average Trading Volume: 402,683
Technical Sentiment Signal: Sell
Current Market Cap: A$1.22B
See more insights into NAN stock on TipRanks’ Stock Analysis page.